Preparation of Micro-spheres Co-carried Anti-tumor Drug and Sensitizer(5-Fu-COS/SeNP) and Their Inhibiting Tumorous Cellular Growths Activity†

doi:10.7503/cjcu20131141

Abstract

Abstract:

5-Fu-COS/SeNP micro-spheres were prepared in two steps to study the antitumor drug load and auxiliary same effects as the drug carrier. First, the Fu-COS prodrug was synthesized with the broad-spectrum anti-tumor drug 5-fluorouracil(5-Fu) and chito-oligosaccharides(COS), then, Fu-COS was used as temples while 5-Fu-COS/SeNP was prepared by sol-gel method. 5-Fu-COS/SeNP was characterized by TEM, Zeta-sizer and IR, and its anti-tumor activity was detected by MTT method. The results showed that 5-Fu and Se were completely carried in 5-Fu-COS/SeNP, the size of 5-Fu-COS/SeNP was 433 nm, the drug-loading rate of 5-Fu and Se were (8.2±0.3)% and (7.96±0.34)%, respectively, and 5-Fu and nanose released slowly and had well inhibiting tumorous cellular growths activity. As time increases, release rate of the drug by Fu-COS/SeNP increased and the inhibition of cell enhanced. After 24 h, inhibition rate had exceeded the sum of 5-Fu and SeNP. After 48 h, the inhibition rate of Fu-COS/SeNP was less than the sum of the inhibition rate of 5-Fu and SeNP, but higher than that of 5-Fu or SeNP. These results indicated that the spheres have high drug loading efficiency and good drug release properties. This novel method to produce micro-spheres could expand the development of drug release research.

Key words: 5-Fluorouracil(5-Fu), Se nanoparticles, Nanomicro-spheres, Anti-tumor activity

CLC Number:

TrendMD:

TONG Chunyi, TANG Fengxia, LIU Bin, LIAO Hongdong, LIU Xuanming. Preparation of Micro-spheres Co-carried Anti-tumor Drug and Sensitizer(5-Fu-COS/SeNP) and Their Inhibiting Tumorous Cellular Growths Activity^†[J]. Chem. J. Chinese Universities, 2014, 35(7): 1603.

Figures/Tables 2

References 20

[1]	Michoda D., Widmann C., Crit. Rev. Oncol. Hemat., 2007, 63(2), 160—171
[2]	Kimura M., Rabbani Z., Mouraviev V., Tsivian M., Caso J., Satoh T., Baba S., Vujaskovic Z., Baust J. M., Baust J. G., Polascik T. J., Urology, 2010, 76(3), 764.e14—764.e20
[3]	Djazayeria K., Szilvássya Z., Benköb K., Rózsaa B., Szabóa B., Szentmiklósia A. J., Benkö I., Pharmacol. Res., 2006, 53(2), 156—161
[4]	Wang H. L., Zhang J. S., Yu H. Q., Acta Nutrimenta Sinica, 2007, 29(5 ),445—447, 452
	(王华丽, 张劲松, 俞汉青. 营养学报, 2007, 29(5),445—447, 452)
[5]	Zhang J., Peng D., Lu H., Liu Q., Toxicol. Appl. Pharm., 2008, 226(3), 251—259
[6]	Chen D. L., Wang J. Y., Wang W. Z., J. Fourth Military Medical University, 1999, 20(1), 41—43
	(陈冬利, 王俊义, 王为忠.. 第四军医大学学报, 1999, 20(1), 41—43)
[7]	Chen D. L., Wang J. Y., Wang W. Z., Parenteral Enteral Nutrition, 1998, 5(1), 18—20
	(陈冬利, 王俊义, 王为忠. 肠外与肠内营养, 1998, 5(1), 18—20)
[8]	Wang Y., Wang X. Y., Lv Y. Y., Xu W. B., Guo Y., Xu L., Chem. J. Chinese Universities, 2013, 34(12), 2866—2870
	(王岩, 王笑英, 吕言云, 许文彬, 郭轶, 徐力. 高等学校化学学报, 2013, 34(12), 2866—2870)
[9]	Chen R., Yang J. R., Yang X. Y., Wang Y. M., Li R. S., Wang R. L., Wang Y. S., Chem. J. Chinese Universities, 2012, 33(7), 1586—1590
	(陈柔, 杨金荣, 杨晓英, 王玉玫, 李蓉珊, 王润玲, 王银松. 高等学校化学学报, 2012, 33(7), 1586—1590)
[10]	Yu F., Xi T. F., Zhang S. J., Zhang Z. X., Lai C., Chem. J. Chinese Universities, 2012, 33(4), 843—849
	(于飞, 奚廷斐, 张姝江, 张志雄, 赖琛. 高等学校化学学报, 2012, 33(4), 843—849)
[11]	Ji J. G., Zhang J. F., Hao S. L., Wu D. J., Liu L., Xu Y., Chem. Res. Chinese Universites, 2012, 28(1), 166—170
[12]	Tong C. Y., Liu B., Li F., Zhang Z. M., Liao H. D., Liu X. M., J. Control Release, 2013, 172(1), e24
[13]	Rajan M., Raj V., Al-Arfaj Abdullah A., Murugan A. M., Int. J. Pharm., 2013, 453(2), 514—522
[14]	Lam P. L., Lee K. K., Wong R. S., Cheng Y. M., Cheng S. Y., Yuen M. C., Lam K. H., Gambari R., Kok S. H., Chui C. H., Bioorg. Med. Chem. Lett., 2012, 22(9), 3213—3218
[15]	Zhu M. X., Zhang J. S., Yang Z. H., Fang Y. C., Gong Y. F., Gao X. Y., Ge G. X., Huang Z., Chinese J. Cancer, 2000, 19(10), 883—886
	(朱茂祥, 张劲松, 杨陟华, 方宇澄, 龚诒芬, 高学云, 葛桂秀, 黄镇. 癌症, 2000, 19(10), 883—886)
[16]	Shi W., Qiao Y. D., J. Jiangxi College of Traditional Chinese Medicine, 2008, 20(1), 61—63
	(施旻, 乔玉丹. 江西中医学院学报, 2008, 20(1), 61—63)
[17]	Luo H. Y., Wang F. F., Bai Y., Chen T. F., Zheng W. J., Colloid Surface B: Biointerfaces, 2012, 94, 304—308
[18]	Yang X.L., Xu B. H., Liao M. Y., Safety of Nano-drug, Science Press, Beijing, 2010, 128
	(杨祥良, 徐辉碧, 廖明阳. 纳米药物安全性, 北京: 科学出版社, 2010, 128)
[19]	Li H. P., Xiao H. W., Long S., Xiao Z. D., Ruan J. M., J. Changsha University of Science and Technology, 2006, 3(4), 91—96
	(李和平, 肖华伍, 龙姝, 肖子丹, 阮建明. 长沙理工大学学报, 2006, 3(4), 91—96)
[20]	Li H. P., Ruan J. M., Cai H. G., Pan T., J. Changsha University of Science and Technology, 2005, 2(4), 84—88
	(李和平, 阮建明, 蔡红革, 潘彤. 长沙理工大学学报, 2005, 2(4), 84—88)